Recombinant Salmonella vaccines for biodefence

被引：19

作者：

Atkins, HS ^{[1
]}

Morton, M

Griffin, KF

Stokes, MGM

Nataro, JP

Titball, RW

机构：

[1] Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England

[2] Univ Maryland, Sch Med, Dept Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA

[3] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England

来源：

VACCINE | 2006年 / 24卷 / 15期

关键词：

Salmonella vaccine; attenuated Salmonella; biodefence;

D O I：

10.1016/j.vaccine.2005.12.046

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

There is a requirement for vaccines to protect against pathogens that may be misused for bioterrorism or biowarfare purposes. In particular, biodefence vaccines are required that may be used for safe and easy immunisation of populations and that can rapidly induce mucosal immunity to provide protection at the lung surface against a range of airborne agents. To address this need, recombinant Salmonella vaccines are being developed. In this review, the technologies used, considerations needed, progress made, and future prospects for developing multivalent Salmonella-based vaccines for biodefence are discussed. Crown Copyright (c) 2006 Published by Elsevier Ltd. All rights reserved.

引用

页码：2710 / 2717

页数：8

共 66 条

[1] Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: Expression levels and immune response [J].

Anderson, R ;

Dougan, G ;

Roberts, M .

VACCINE, 1996, 14 (14) :1384-1390

[2] Oral delivery of foreign antigens by attenuated Salmonella: Consequences of prior exposure to the vector strain [J].

Attridge, SR ;

Davies, R ;

LaBrooy, JT .

VACCINE, 1997, 15 (02) :155-162

[3]

BAO J X, 1991, Infection and Immunity, V59, P3841

[4] Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters [J].

Bullifent, HL ;

Griffin, KF ;

Jones, SM ;

Yates, A ;

Harrington, L ;

Titball, RW .

VACCINE, 2000, 18 (24) :2668-2676

[5]

CARDENAS L, 1993, INFECT IMMUN, V61, P4629

[6]

CARDENAS L, 1992, CLIN MICROBIOL REV, V5, P328

[7] EXPRESSION AND IMMUNOGENICITY OF THE V3 LOOP FROM THE ENVELOPE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN AN ATTENUATED AROA STRAIN OF SALMONELLA-TYPHIMURIUM UPON GENETIC COUPLING TO 2 ESCHERICHIA-COLI CARRIER PROTEINS [J].

CHARBIT, A ;

MARTINEAU, P ;

RONCO, J ;

LECLERC, C ;

LOMAN, R ;

MICHEL, V ;

OCALLAGHAN, D ;

HOFNUNG, M .

VACCINE, 1993, 11 (12) :1221-1228

[8] USE OF THE NIRB PROMOTER TO DIRECT THE STABLE EXPRESSION OF HETEROLOGOUS ANTIGENS IN SALMONELLA ORAL VACCINE STRAINS - DEVELOPMENT OF A SINGLE-DOSE ORAL TETANUS VACCINE [J].

CHATFIELD, SN ;

CHARLES, IG ;

MAKOFF, AJ ;

OXER, MD ;

DOUGAN, G ;

PICKARD, D ;

SLATER, D ;

FAIRWEATHER, NF .

BIO-TECHNOLOGY, 1992, 10 (08) :888-892

[9]

CHATFIELD SN, 1994, MODERN VACCINOLOGY, P55

[10] Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. typhimurium [J].

Dunstan, SJ ;

Simmons, CP ;

Strugnell, RA .

INFECTION AND IMMUNITY, 1999, 67 (10) :5133-5141

← 1 2 3 4 5 6 7 →